AI-Native Biotechnology
How artificial intelligence changes scientific workflows, organizational design, decision-making, and the operating model of biotechnology companies.
Insights
Perspectives on building biotechnology companies.
Michael Churchill writes about company building, translational strategy, precision medicine, scientific leadership, commercialization, and the practical use of AI in biotechnology organizations.
Attenuated Technologies provides the publishing platform for practical ideas developed through building companies, teams, platforms, and clinical capabilities.
Essays in development
The first essays are being developed as durable perspectives rather than as a high-frequency news or commentary stream.
Each piece will be designed to remain useful beyond the week it is published.
Michael Churchill, Ph.D.Founder & Principal, Attenuated Technologies
Areas of inquiry
The writing examines questions where scientific choices, company strategy, technology, and organizational design intersect.
Translational Strategy
How scientific hypotheses, biomarkers, clinical evidence, development risk, and cross-functional execution connect.
Scientific Organizations
How teams, incentives, interfaces, governance, and decision systems shape scientific output.
Company Building
Lessons from forming biotechnology companies, defining platforms, recruiting teams, financing programs, and navigating growth or acquisition.
Diagnostics and Precision Medicine
Perspectives on multimodal data, clinical utility, assay strategy, product development, and commercialization.
Commercialization and Execution
How scientific platforms become products, clinical capabilities, and durable operating systems.